SCHEMBL19779083

SCHEMBL19779083

CC1(C)O[C@@H]2[C@H](O1)[C@@H](CO[Si](C)(C)C(C)(C)C)O[C@H]2c1ccc2c(N)ncnn12

nearest known ligand 0.39

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ POLRMT O00411 1/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.34
▸ PI4KA P42356 1/20 0.32
▸ PI4K2B Q8TCG2 1/20 0.32
▸ PI4K2A Q9BTU6 1/20 0.32
▸ PI4KB Q9UBF8 1/20 0.32
▸ P2RX1 P51575 1/20 0.32
▸ P2RX3 P56373 1/20 0.32
▸ P2RX4 Q99571 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25224367 0.84 — —
SCHEMBL16708543 0.84 POLRMT (0.37) POLRMTRXFP1PI4KAPI4K2BPI4K2A
SCHEMBL15605903 0.84 POLRMT (0.37) POLRMTRXFP1PI4KAPI4K2BPI4K2A
SCHEMBL16699384 0.83 ALDH1A1 (0.33) —
SCHEMBL16710454 0.83 PI4KA (0.47) POLRMTRXFP1PI4KAPI4K2BPI4K2A
SCHEMBL13532207 0.83 PI4KA (0.47) POLRMTRXFP1PI4KAPI4K2BPI4K2A
SCHEMBL19344228 0.83 POLRMT (0.37) POLRMTRXFP1PI4KAPI4K2BPI4K2A
SCHEMBL19779236 0.81 CYP3A4 (0.34) —
SCHEMBL15718024 0.80 POLRMT (0.32) POLRMT
SCHEMBL24606260 0.80 POLRMT (0.37) POLRMTRXFP1PI4KAPI4K2BPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4122932-A1 PYRROLO[1,2-F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS Gilead Sciences, Inc. (US) 2023-01-25 — — EP disclosed
EP-3505173-B1 PYRROLO[1,2-F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS GILEAD SCIENCES INC (US) 2022-07-06 — — EP disclosed
US-10377761-B2 Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections GILEAD SCIENCES, INC. (US) 2019-08-13 — — US disclosed
US-10377761-B2 Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections GILEAD SCIENCES, INC. (US) 2019-08-13 — — US disclosed
EP-3505173-A1 PYRROLO[1,2-F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS Gilead Sciences, Inc. (US) 2019-07-03 — — EP disclosed
EP-3068405-B1 PYRROLO [1,2,F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS GILEAD SCIENCES INC (US) 2019-05-01 — — EP disclosed
US-20190055253-A1 PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS GILEAD SCIENCES, INC. 2019-02-21 — — US disclosed
US-20180016280-A1 PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS GILEAD SCIENCES, INC. 2018-01-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016280-A1 PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS SYNJ1, SARS1, SYNJ2 POLRMT 306/4885RXFP1 536/4885PI4KA 3453/4885
US-10377761-B2 Pyrrolo[1,2-f][1,2,4]triazines useful for treating respiratory syncitial virus infections SYNJ1, SARS1, SYNJ2 POLRMT 306/4885RXFP1 536/4885PI4KA 3453/4885
US-20190055253-A1 PYRROLO[1,2-f][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS SYNJ1, SARS1, SYNJ2 POLRMT 306/4885RXFP1 536/4885PI4KA 3453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback